Tim Hohm to further develop Optibrium’s sales and business strategy for global market expansion
CAMBRIDGE, UK, 17 February, 2020 – Optibrium™, a developer of software for drug discovery, today announced the appointment of Dr Tim Hohm as Director of Commercial Strategy and Business Development. Tim will be responsible for leading the Company’s commercial strategy and sales processes, with a focus on further expanding Optibrium’s global customer base. In addition to managing existing customer relationships and new business opportunities, Tim’s role will involve market and customer insight in relation to the Company’s StarDrop™ and Augmented Chemistry™ products and services, helping to guide the continued development of Optibrium’s in silico drug discovery technologies and artificial intelligence services.
Tim joins Optibrium from Novo Nordisk where he held a position as Senior Competitive Intelligence Manager. His role at Novo Nordisk covered digital health and delivery technology with responsibilities including strategy development, defining target product profiles and building business cases for pipeline projects and external opportunities. Tim has a PhD in Computational Biology from ETH Zurich and research experience with optimisation heuristics and quantitative modelling of gene regulatory networks. Tim’s natural sciences background is complemented with an MBA from the internationally recognised Copenhagen Business School.
Dr Matthew Segall, CEO at Optibrium, said: “Tim’s background in business strategy, and combined experience in the drug development value chain, pharmaceutical research and development and computational sciences, will be invaluable in attaining our ambitious expansion plans and sustained commercial growth. We are delighted to welcome Tim to oursenior team and look forward to him developing Optibrium’s global customer base, supporting our objectives to extend and enhance our innovative drug discovery software and services.”
Dr Tim Hohm, Director of Commercial Strategy and Business Development at Optibrium, said: “I am pleased to be joining Optibrium at this exciting time, following the launch of the Company’s StarDrop™ 6.6 software and recent introduction of the new Augmented Chemistry™ platform. I look forward to working with the team to support these products, engage with Optibrium’s existing customers and develop new opportunities to further expand the global user base.”